Sugi Predict

Sugi Predict / Compounds / SCHEMBL3609310

SCHEMBL3609310

SCHEMBL3609310

CCOC(=O)c1ccsc1-c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 3/20 0.58
▸ ALDH1A1 P00352 10/20 0.54
▸ MAPT P10636 6/20 0.54
▸ HPGD P15428 5/20 0.54
▸ SMN1; SMN2 Q16637 5/20 0.54
▸ GRM6 O15303 4/20 0.54
▸ GAA P10253 3/20 0.54
▸ RAB9A P51151 3/20 0.54
▸ NPSR1 Q6W5P4 3/20 0.54
▸ HSD17B10 Q99714 2/20 0.54
▸ ALOX15 P16050 1/20 0.54
▸ LMNA P02545 3/20 0.51
▸ MAPK1 P28482 1/20 0.49
▸ ATM Q13315 1/20 0.49
▸ NPC1 O15118 2/20 0.48
▸ TP53 P04637 1/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ CDC7 O00311 1/20 0.47
▸ TRPM8 Q7Z2W7 1/20 0.47
▸ DBF4 Q9UBU7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3321379 0.81 KDM4E (0.56) TSHRALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL23079540 0.81 ALDH1A1 (0.52) TSHRALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL24208929 0.80 MAPT (0.62) MAPTSMN1; SMN2GAARAB9A
SCHEMBL29790149 0.79 GRM6 (0.44) TSHRALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL20028742 0.78 ALDH1A1 (0.58) TSHRALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL1844052 0.78 TSHR (0.57) TSHRALDH1A1MAPTHPGDGAA
SCHEMBL20042499 0.77 TSHR (0.45) TSHRALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL976420 0.77 ALDH1A1 (0.72) TSHRALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL3052561 0.77 MAPK1 (0.58) TSHRALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL5240541 0.77 TSHR (0.52) TSHRALDH1A1MAPTHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116478128-A Polysubstituted 2-thiothiophene compound and preparation method thereof 浙江大学 2023-07-25 — — CN claimed
CN-116478128-A Polysubstituted 2-thiothiophene compound and preparation method thereof 浙江大学 2023-07-25 — — CN disclosed
US-11339130-B1 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2022-05-24 — — US disclosed
US-10934261-B2 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2021-03-02 — — US disclosed
US-10894776-B2 — — 2021-01-19 — — US disclosed
WO-2018064119-A1 CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF BLADE THERAPEUTICS, INC. (US) 2018-04-05 — — WO disclosed
US-9051266-B2 Carbazole derivatives and organic light emitting diodes comprising the same INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2015-06-09 — — US disclosed
US-9051266-B2 Carbazole derivatives and organic light emitting diodes comprising the same INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2015-06-09 — — US disclosed
EP-2627632-A1 SULPHONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME Zafgen, Inc. (US) 2013-08-21 — — EP disclosed
US-20130105767-A1 CARBAZOLE DERIVATIVES AND ORGANIC LIGHT EMITTING DIODES COMPRISING THE SAME INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2013-05-02 — — US disclosed
US-20130105767-A1 CARBAZOLE DERIVATIVES AND ORGANIC LIGHT EMITTING DIODES COMPRISING THE SAME INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2013-05-02 — — US disclosed
US-8193215-B2 Thieno[2 3-b]pyridines as potassium channel inhibitors XENTION LIMITED (GB) 2012-06-05 — — US disclosed
WO-2012051318-A1 SULPHONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN CORPORATION (US) 2012-04-19 — — WO disclosed
US-20100041695-A1 Thieno[2,3-b]pyridines as Potassium Channel Inhibitors XENTION LIMITED (GB) 2010-02-18 — — US disclosed
US-7576212-B2 Thieno[2,3-B] pyridines as potassium channel inhibitors XENTION LIMITED (GB) 2009-08-18 — — US disclosed
US-20060183768-A1 Compounds XENTION DISCOVERY LTD. (GB) 2006-08-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934261-B2 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 TSHR 4380/4885ALDH1A1 4193/4885MAPT 562/4885
US-20100041695-A1 Thieno[2,3-b]pyridines as Potassium Channel Inhibitors SCN8A, SCN1B, SCN2B TSHR 151/4885ALDH1A1 3155/4885MAPT 4755/4885
US-10894776-B2 — CAPNS1, CAPN9, CAPN2 TSHR 4691/4885ALDH1A1 4421/4885MAPT 330/4885
US-20060183768-A1 Compounds SCN7A, CBR3, SCN8A TSHR 164/4885ALDH1A1 2799/4885MAPT 4795/4885
US-11339130-B1 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 TSHR 4380/4885ALDH1A1 4193/4885MAPT 562/4885
US-20130105767-A1 CARBAZOLE DERIVATIVES AND ORGANIC LIGHT EMITTING DIODES COMPRISING THE SAME DRD1, DRD3, DOT1L TSHR 1920/4885ALDH1A1 122/4885MAPT 2065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.